Capricor Therapeutics (NASDAQ:CAPR) posted its quarterly earnings results on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01), Yahoo Finance reports. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.63 million.
Shares of CAPR stock opened at $1.28 on Friday. The company has a market capitalization of $37.97, a P/E ratio of -2.91 and a beta of -3.29. Capricor Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $4.25.
CAPR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $8.60 target price (up from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, February 13th.
COPYRIGHT VIOLATION NOTICE: “Capricor Therapeutics (NASDAQ:CAPR) Issues Quarterly Earnings Results” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/capricor-therapeutics-capr-issues-quarterly-earnings-results-misses-expectations-by-0-01-eps.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.